^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Alymsys (bevacizumab-maly) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Published date:
    04/13/2022
    Excerpt:
    Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of...Metastatic renal cell carcinoma in combination with interferon alfa.
    Secondary therapy:
    alpha-interferon
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    PRNewswire
    Title:

    European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer

    Published date:
    03/31/2021
    Excerpt:
    ...The European Commission (EC) has approved mAbxience's MB02 biosimilar to Avastin® (Bevacizumab), in Europe....MB02, to be commercialized as Alymsys® and Oyavas®...MB02 is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.